PHARMACEUTICAL 2026

Alnylam Pharmaceuticals INC
Rank 114 of 178



PHARMACEUTICAL 2026

Alnylam Pharmaceuticals INC
Rank 114 of 178

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 44% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 46% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	4,050,662
Cost of Goods Sold	677,166
Intangible Assets	0
Liabilities, Current	1,466,349
Liabilities, Non-Current	232,681
Other Assets	402,522
Other Compr. Net Income	14,421
Other Expenses	14,110
Other Liabilities	2,478,125
Other Net Income	-178,426
Other Revenues	3,713,937
Property and Equipment	513,147
Research and Development	1,319,775
Selling, General and Administrative Expense	1,210,713

Output Variable	Value in 1000 USD
Assets	4,966,331
Liabilities	4,177,155
Expenses	3,221,764
Revenues	3,713,937
Stockholders Equity	789,176
Net Income	313,747
Comprehensive Net Income	320,958
BaseVar	8,136,017
ECR before LimitedLiability	45%
Economic Capital Ratio	183%